The toxic effects of tumor necrosis factor ␣ (TNF␣) have greatly limited its use in tumor therapy. Recently, clear evidence has been obtained linking the p55 TNF receptor (TNFR) to the induction of systemic toxicity. We have generated a p75 murine TNFR (mTNFR)-specific mutant of mTNF␣ (D142N-A144R), cloned this gene into a recombinant adenovirus vector (Ad-75), and studied its efficacy for tumor immunotherapy of a murine transgenic breast cancer model. Cell culture supernatants from Ad-75-transduced cells showed no cytotoxic activity on L929 cells, but retained the ability to induce proliferation of a murine T-cell line (CT6); this activity was not blocked by soluble p55 mTNFR. Furthermore, it was shown that the mutant form of mTNF␣ was able to coimmunoprecipitate only with the p75 mTNFR and not with the p55 mTNFR. Tumors injected with Ad-75 became necrotic, and mice injected with Յ1 ϫ 10 9 plaque-forming units showed no mortality, whereas both wild-type murine and human TNF vectors induced lethality at doses of 1 and 5 ϫ 10 8 plaque-forming units. All Ad-TNF vectors induced partial or permanent tumor regressions, with cured mice showing immune memory against the tumor. These results demonstrate that a p75 mTNFR agonist expressed from a recombinant adenovirus vector does not induce mortality at doses that cause tumor regression.
T umor necrosis factor ␣ (TNF␣) was first identified through the detection of antitumor activity in the sera of mice treated with endotoxin. 1 Mature TNF␣ is a 17-kDa polypeptide that recognizes two cell surface receptors (p55 and p75 TNF receptors (TNFRs)). 2 These receptors are highly homologous in their extracellular domains, but show little homology between their intracellular domains, and are believed to act via distinct signal transduction pathways. 3, 4 The p55 TNFR is primarily responsible for signaling a variety of responses, including cytotoxicity 2, 5 and cytokine secretion, 6 whereas the p75 TNFR is primarily responsible for lymphoproliferative signals and the activation of T cells 5, 7 TNFRs are ubiquitously expressed on nearly all cell types; however, the p75 TNFR is preferentially expressed by lymphoid cells.
Human TNF␣ (hTNF␣) does not recognize the murine p75 TNFR but does bind to the p55 TNFR. 8, 9 Also, it is estimated that hTNF␣ is 50 times less toxic in mice compared with the murine form. 2 This observation suggested that the p75 TNFR is primarily responsible for the induction of systemic toxicity; however, it has become clear in recent years that the reduced toxicity exhibited by hTNF␣ in mice is a result of the lack of cooperation between signaling through both receptors and not of a lack of activation of the p75 TNFR. Furthermore, it is now believed that the p55 TNFR is primarily responsible for the induction of systemic toxicity. 10 -12 The treatment of cancer with a p75 TNFR-specific agonist should result in greatly reduced systemic toxicity compared with that induced by wild-type (wt) TNF␣, as well as being able to activate an antitumor immune response. Point mutants of hTNF␣ have been generated that show specificity for either the p55 hTNFR or the p75 hTNFR. 13, 14 Because hTNF␣ and murine TNF␣ (mTNF␣) are highly homologous, particularly in the domains that recognize the p55 TNFR, we constructed a point mutant of mTNF␣ (D142N-A144R) analogous to the hTNF mutant (D143N-A145R). 13 Following rescue of this mutant gene into an adenovirus (Ad) vector, we were able to demonstrate that this murine mutant is p75 mTNFR-specific. In addition, we have investigated the efficacy of an Ad expressing this mutant for tumor immunotherapy.
MATERIALS AND METHODS

Cell culture
Cell culture media and reagents were purchased from Life Technologies (Missasauga, Ontario, Canada) with the exception of Fungizone, which was purchased from Squibb (Montreal, Quebec, Canada). MRC5 (human lung fibroblasts) cells (CCL-171; American Type Culture Collection, Manassas, Va) were cultured in ␣-minimal essential medium. Ad-5 E1-complementing human embryonic kidney cells (293), MT1A2 cells (a line derived from polyoma middle-T (PyMidT) transgenic primary mammary tumor cells), and transgenic PyMidT primary tumor cells were cultured in minimal essential medium-F11. [15] [16] [17] [18] The NDL cell line (generated from mutant transgenic neu mammary tumor cells) was cultured in Dulbecco's modified Eagle's medium supplemented with 30 ng/mL epidermal growth factor (Boehringer Mannheim, Laval, Quebec, Canada). 19 The TNF␣-sensitive murine cell line L929 was cultured in RPMI 1640 supplemented with 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine, 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, and 10% fetal bovine sera (FBS). CT6 cells (murine T cells) were also cultured in RPMI 1640 supplemented with 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2 mM L-glutamine, 10 M B-mercaptoethanol, 20 U/mL interleukin-2 (IL-2) (Life Technologies), and 10% FBS. All other cell culture medium was supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2.5 g/mL Fungizone, and 10% FBS.
Vector construction
A cDNA encoding the mature (i.e., secreted form) of mTNF␣ cDNA fused with the interferon-␥ (IFN-␥) signal peptide cDNA was mutated using the four primer polymerase chain reaction technique with the primers 5Ј-GGCTATTGAAAC-TAATGCAA-3Ј (outside rightward), 5Ј-ACAATGCTTC-CATCAAACGA-3Ј (outside leftward), 5Ј-AAGTAC-TTAAACTTTCGGGAGTCCGGG-3Ј (inside rightward), 5Ј-CCCGGACTCCCGAAAGTTTAAGTACTT-3Ј (inside leftward), Vent polymerase (New England Biolabs, Missasauga, Ontario, Canada), and the plasmid pV1L-TNF (containing the construct) as the template. 20 The double point mutant (D142N-A144R) was cloned into pMH4 creating the plasmid pmTNF-75. 21 The Ad-mTNF-75 (Ad-75) (Fig 1) vector was generated by in vivo recombination between the Ad-genomic plasmid pBHG10 and the shuttle plasmid pmTNF-75, which express the mutant secreted mTNF␣ cDNA under the control of the murine cytomegalovirus (MCMV) promoter and the simian virus 40 (SV40) polyadenylation signal. 22 Ad vectors were isolated, propagated in 293 cells, and purified (in CsCl gradients) as described previously. 23 
Expression assay preparation
In vitro expression assays were performed by infecting cells at multiplicities of infection (MOIs) of 1, 10, and 50 plaqueforming units (PFU) per cell, sampling cell culture supernatants at various timepoints postinfection, and storing samples at Ϫ70°C until the time of assay.
TNF␣ bioassay/cytotoxicity assay
The cytotoxicity bioassay measured direct killing of a TNFsensitive cell line (L929). Cells were dispensed into 96-well plates (5 ϫ 10 4 cells in 50 L) and incubated overnight at 37°C (ϳ20 hours) in growth medium. The following day, the medium was aspirated and replaced with 40 L of medium plus soyabean trypsin inhibitor (100 g/mL) and cycloheximide (Sigma, St. Louis, Mo) (20 g/mL). A total of 10 L of samples or standards was added to the microtiter wells and incubated at 37°C overnight (ϳ18 hours). Afterward, 10 L of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was added to each well and incubated for 4 hours, after which 50 L of 50% dimethylformamide (20% sodium dodecyl sulfate (SDS), pH 4.7) was added. Following an additional overnight incubation, the optical density (OD) 570 was measured. For the quantitation of TNF␣, the measured OD 570 from diluted samples was compared with the OD 570 obtained from serial dilutions of a standard recombinant TNF␣ stock solution. Cycloheximide, soyabean trypsin inhibitor, MTT, and recombinant mTNF␣ used as the standard were purchased from Sigma. Recombinant hTNF␣ was purchased from R&D Systems (Minneapolis, Minn). 
CT6 proliferation assay
Receptor binding by TNF in vitro
For coimmunoprecipitations 500 L of NDL cell culture supernatants from Ad vector transduced cells (MOI of 50 PFU/cell) were coimmunoprecipitated with 2 g of hamster anti-p55 mTNFR antibody (Ab) (55R-286) or hamster antip75 mTNFR Ab (TR75-89) (both acquired from Dr. Robert D. Schreiber's laboratory, Washington University, St. Louis, Mo) 12 or with 2 g of soluble p55 mTNFR or p75 mTNFR, respectively (R&D Systems), as well as protein G-Sepharose (Pharmacia Biotech, Quebec, Ontario, Canada) (100 L preswollen slurry) in phosphate-buffered saline (PBS) for 4 hours. Neither mTNFR Ab blocked TNF␣ binding. Sepharose beads were washed six times in PBS.
Samples were analyzed by SDS polyacrylamide gel electrophoresis on a 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (Immobilon-P; Millipore, Bedford, Mass). Western blotting was done by blocking the membrane with 5% powdered milk in PBS and subsequently incubating with primary polyclonal goat anti-mouse TNF␣ Ab (R&D Systems) for 4 hours at room temperature or overnight at 4°C. After extensive washing, the membrane was incubated with secondary horseradish peroxidase-conjugated donkey antigoat Ab (Santa Cruz Biotechnology, Santa Cruz, Calif) for 4 hours at room temperature. For the detection of hTNF␣, polyclonal rabbit anti-mouse hTNF␣ Ab was used as the primary Ab (Chiron) (2 hours at room temperature); horseradish peroxidase-conjugated goat anti-rabbit Ab was used as the secondary Ab (Santa Cruz Biotechnology) (1 hour at room temperature); detection hTNF␣ was done after blotting for the murine form.
Tumor studies
Transgenic mice carrying the PyMidT oncogene under the mouse mammary tumor virus promoter/enhancer were generated by Guy et al. 18 Breast tumors from transgenic females were explanted and homogenized in collagenase (0.025% w/v) and dispase (0.25% w/v) (Boehringer Mannheim). Next, tumor cells were cultured for 24 -48 hours at 37°C (until confluent) and subsequently trypsinized (0.1% trypsin, 1.06 mM ethylenediaminetetraacetic acid in PBS; Sigma), washed, and resuspended in PBS, after which they were injected subcutaneously into syngeneic FVB mice (5 ϫ 
Tumor morphology
Tumors were removed from treated mice, cut in two with a razor, and fixed in 10% neutral-buffered formalin for 18 -24 hours. After fixation, the tissue was immersed in 50% ethanol and subsequently in 60% ethanol for 30-minute periods until finally being stored in 70% ethanol. Next, Tumors were paraffin-embedded, sectioned, and stained with hematoxylin and eosin (H&E).
RESULTS
In vitro expression of Ad-mTNF-75
For optimal p75 TNFR specificity, 13 a double point mutant of mTNF␣ (D142N-A144R) was constructed similar to that reported previously for hTNF␣ (see Materials and Methods). This mutant murine cDNA fused with the IFN-␥ signal peptide coding sequences expressed under the control of the MCMV immediate early promoter and a downstream SV40 polyadenylation signal was rescued into an E1/E3-deleted Ad type 5 vector (Ad-mTNF-75) (Fig 1) . Other vectors expressing the wt murine and human forms of TNF␣ under the control of the MCMV promoter were also used. 24, 25 To determine whether Ad-mTNF-75 induced expression of the mutant TNF␣ cDNA, human fibroblast MRC5 and mouse adenocarcinoma-derived NDL and 25 vectors express the mature mTNF␣ and hTNF␣ cDNAs, respectively, fused with the IFN-␥ signal peptide. Ad-mTNF (Ad-mTNF-wt) 24 contains the entire mTNF␣ cDNA. All TNF␣-expressing vectors use the MCMV promoter and an SV40 polyadenylation signal. All vectors are E1/E3-deleted Ad-5-based vectors.
MT1A2 cells were transduced with Ad-mTNF-75 at MOIs of 1, 10, and 50 PFU/cell. For comparison, cells were also transduced with Ad vectors expressing wt mTNF␣ (Ad-mTNF-wt or Ad-mTNF), 24 wt hTNF␣ (Ad-MCMV-TNF or Ad-hTNF) 25 (Fig 1) , or an E1/E3-deleted control vector (Ad-BHG⌬E1,3). Expression of the mutant protein was detected by Western blot analysis with a polyclonal anti-mouse TNF␣ Ab (Fig 2) . Comparable expression levels of mutant and wt mTNF␣ were detected from transduced MT1A2 cells (Fig 2,  lanes 4 and 7) . Furthermore, expression of mutant mTNF␣ was also detected in transduced NDL and MRC5 cells (Fig 2, lanes 5 and 6) . Interestingly, it seems that the electrophoretic mobility of the mutant mTNF␣ band is slightly greater than that of wt TNF␣. The expression levels of wt hTNF␣ and mTNF␣ were quantitated by a bioactivity assay using a TNF␣-sensitive cell line (L929). Levels of TNF␣ up to ϳ500 ng/mL were detected in culture supernatant from transduced murine cells, and ϳ5-to 10-fold lower levels were detected from infected human MRC5 cells (Table 1) .
Cytotoxicity and proliferation assays
The induction of cytotoxicity by TNF␣ is primarily signaled through the p55 TNFR.
2,5 Therefore, we tested the cytotoxic activity of cell culture supernatants from cells transduced with the mutant and wt TNF␣ vectors on the well-characterized L929 cell line. Both wt mTNF␣ (p55 and p75 TNFR-specific) and hTNF␣ (p55 TNFR-specific) expressed from MRC5, NDL, and MT1A2 cells were cytotoxic to L929 cells, as was demonstrated by greatly reduced absorbance (570 nm) levels (Fig 3A) , indicating the lack of chromogenic processing of MTT by viable cells (see Materials and Methods). However, no cytotoxic activity was detected from cells transduced with the Ad-75 vector when compared with a control Ad-BHG⌬E1,3 vector. The cytotoxicity generated by standard concentrations of recombinant mTNF␣ showed that near background absorbance (i.e., maximal cytotoxicity) was induced by a concentration of only 2000 pg/mL. The approximate concentration of mutant TNF␣ in the cell culture supernatant was similar to that of Ad-mTNF-transduced cells (Ӎ400 ng/mL) as estimated by Western blot analysis (Fig 2) . Thus, even at a mutant mTNF␣ concentration that was ϳ100 -200 times higher than that needed to induce maximal cell death by recombinant wt protein, no cytotoxicity was observed. These data strongly suggest that the mutant form of mTNF␣ no longer binds to the p55 mTNFR. Proliferative signals are commonly induced through activation of the p75 TNFR. 5 ,12 Therefore, we tested the ability of cell culture supernatants from cells transduced with the mutant and wt vectors to induce the proliferation of a murine T-cell line (CT6) (proliferation was measured by MTT as well) (see Materials and Methods). All three forms of TNF␣ induced the proliferation of CT6 cells (Fig 3B) , with the wt and mutant mTNF␣ vectors inducing the highest levels. Furthermore, the addition of soluble murine p55 TNFR blocked activity by both mTNF␣ and hTNF␣ but had no effect on the mutant form. The ability of the mutant protein to induce the proliferation of CT6 cells in both the presence and absence of soluble p55 mTNFR suggests that the mutant specifically activates only the p75 mTNFR.
In vitro binding of mutant and wt TNF␣ to TNFRs
The physical associations of the various forms of TNF␣ with the murine p55 and p75 TNFRs were demonstrated by coimmunoprecipitating ligands secreted by vectorinfected cells with soluble forms of the receptors. Hamster anti-mouse p55 and p75 mTNFR Abs were used to immunoprecipitate the murine receptors. Both of these Abs were chosen for their ability to bind the respective receptor without blocking TNF binding. 12 Coimmunoprecipitates were analyzed by Western blot analysis with primary anti-mouse TNF␣ and primary anti-human TNF␣ Abs. The wt mTNF␣ was coprecipitated with both p55 and p75 mTNFR (Fig 4, lanes 2 and 3) . However, only the p75 and p55 mTNFR coprecipitated the mutant murine and wt human forms of TNF␣, respectively (Fig  4, lanes 7 and 10) . Unknown cross-reacting bands appeared at ϳ30 kDa in all sample and control lanes. In all cases, TNF␣ was not precipitated in the absence of either mTNFR. These results clearly demonstrate that the double point mutant (D142N-A144R) specifically binds to the murine p75 TNFR.
Effect of the mutant form of mTNF␣ on tumor pathology Mice bearing transplanted PyMidT were injected intratumorally (i.t.) with 5 ϫ 10 8 PFU of Ad vectors. At 2 days postinjection, the tumors were removed from sacrificed mice and processed for paraffin sectioning. H&E stains of tumor sections showed that, by comparison with normal tumor morphology as exhibited by tumors injected with control vector (Fig 5A) , the mutant form of mTNF␣ was able to induce i.t. necrosis (Fig 5B) , as did the wt vectors (Fig 5, C and D) ; however, the extent of the necrosis induced by Ad-75 was significantly lower. It should also be noted that the Ad-75 vector did not induce significant levels of necrosis at a lower dose of 1 ϫ 10 8 PFU (data not shown), whereas it has been determined previously that both wt vectors readily induced i.t. necrosis at that dose. 24, 25 Systemic and antitumor effects of the mutant form of mTNF␣ Previous studies have suggested that the triggering of the p55 and not the p75 TNFR is primarily responsible for the induction of systemic toxicity, 10 -12 and that triggering of the p75 TNFR is responsible for signaling the activation/proliferation of lymphoid cells. Therefore, we decided to test the systemic/antitumor effects of the Ad-75 vector directly injected into PyMidT tumors. Both of the wt TNF␣-expressing vectors (Ad-mTNF and Ad-hTNF) have been tested previously in this tumor model. 24, 25 These vectors proved to be quite toxic to treated mice, killing 12 of 16 and 8 of 20 injected animals in two experiments and curing 2 of 4 and 1 of 12 mice, respectively, at a dose of 5 ϫ 10 8 PFU/mouse. We chose to use these vectors along with the mutant vector for a direct comparison in vivo. Table 2 shows the results of the immunotherapy treatments with the various Ad vectors. The Ad-75 vector showed no mortality even at a dose of 1 ϫ 10 9 PFU, which in previous experiments with both wt vectors resulted in 100% mortality within 1-3 days. 24, 25 Both wt vectors showed lethality at doses of 5 and 1 ϫ 10 8 PFU, killing two of four and three of eight mice (Ad-mTNF) and three of five and one of five mice (Ad-hTNF), respectively. No gross toxicity was observed in control vector-injected mice. Even though the Ad-75 vector showed no mortality, it did induce an antitumor response in treated mice, causing partial regressions in 5 of 15 mice and permanent elimination of the tumor in 2 of 15 mice at a dose of 5 ϫ 10 8 PFU. Mice surviving treatment with the wt vectors also showed an antitumor response, with one in two being cured at a dose of 5 ϫ 10 8 PFU (Ad-mTNF) and one in four being cured at a dose of 1 ϫ 10 8 PFU (Ad-hTNF), as well as inducing partial regressions (see Table 2 ). Figure 6 displays the growth kinetics typically exhibited by tumors treated with Ad-75 (5 ϫ 10 8 PFU). All mice cured in these experiments were resistant to subsequent challenge (2 months later) with PyMidT tumor cells, which implied the induction of immune memory against the tumor. These data clearly show that a TNF␣ mutant that functions through activation of the p75 mTNFR alone does not induce gross mortality while retaining the ability to induce an antitumor response.
DISCUSSION
The p55 TNFR has been implicated as the primary receptor for the induction of systemic toxicity by TNF␣. 10 -12 Our in vivo experiment data support this conclusion by showing that, compared with the wt forms of mTNF␣ and hTNF␣, a p75 TNFR-specific form showed no lethality; however, less obvious side effects may have been present. Furthermore, the fact that p75 TNFR activation does have immune stimulatory properties 3, 5, 7 allows one to specifically bypass TNF␣-related toxicity while retaining the ability to activate an antitumor response. Here, we have shown such an application of a p75 TNFR-specific ligand and compared it with ligands that bind both receptors (mTNF␣) or the p55 receptor alone (hTNF␣).
We have not yet fully characterized the nature of the antitumor response induced by this receptor-specific mutant; however, the detection of immune memory against the tumor suggests that an immune response is involved. In addition, it has been demonstrated that mice cured by cytokine-expressing Ad vectors, including Ad-mTNF and Ad-75, 24, 26 showed PyMidT-specific cytotoxic T-lymphocyte activity (data not shown). The one mouse cured by the hTNF␣ vector has yet to be tested for PyMidT specific-cytotoxic T-lymphocyte activity. The role of the immune system in the antitumor activity of TNF␣ is well established. 7, [27] [28] [29] [30] By comparing the effects of hTNF␣ and mTNF␣ on murine T-cell lines transfected with the human p75 TNFR cDNA, Vandenabeele et al. 7 showed that activation of the p75 TNFR was able to specifically induce cytokine secretion by T cells. Recently, the effects of the administration of a p75 TNFR-specific mutant of hTNF␣ were tested in baboons, 31 and the results of this study indicated that this form of TNF␣ did not induce hypotension, IL-6 or IL-8 production, or skin necrosis as did wt and p55 TNFRspecific ligands. However, a modest infiltration of lymphocytes and macrophages was detected in the dermis.
A comparison of the effectiveness of the Ad-75 vector at doses of 5 ϫ 10 8 and 1 ϫ 10 9 PFU indicates a potential inhibitory effect at higher doses; however, greater numbers of mice are needed to confirm this possibility (see Table 2 ). TNF␣ has been implicated as part of the immune regulatory mechanism modulating T-cell responses through the elimination of reactive T cells. 32, 33 TNF␣ was shown to be an important mediator of T-cell anergy in HIV infection, and TNF␣ alone was shown to inhibit CD4 ϩ T-cell function. 34 Other examples of the suppressive properties of TNF␣ have been described previously. 35, 36 Perhaps the higher levels of mutant mTNF␣ produced at the dose of 1 ϫ 10 9 PFU induced an immunosuppressive response.
The data presented in Table 2 show that exclusive activation of the p55 TNFR by hTNF␣ can produce an antitumor response in up to half of treated animals. The p55 TNFR is a powerful inducer of a variety of immunologic/antitumor activities, including the induction of cytokine secretion, neutrophil activation, endothelial cell activation, 6, 27, 37, 38 and cytotoxicity. 2, 5 The induction of i.t. thrombosis is a major mechanism by which TNF␣ can induce rapid tumor necrosis. 2,39 -41 As well, Van der Poll et al 38 demonstrated that only wt and p55-specific agonists induced coagulation and fibrinolysis in baboons. Considering the dominant role of the p55 TNFR in endothelial cell activation and cytotoxicity, one would not predict that a p75 TNFR-specific agonist would induce i.t. necrosis in contrast with our observations (Fig  5) . However, we did note that the degree to which the necrosis was induced was somewhat less in Ad-75-treated mice. It is possible that the overproduction of TNF␣ generated by the Ad vector could account for this *Mortality represents the proportion of mice that died as a result of vector administration, typically within 1-4 days postinjection. †Partial response refers to the proportion of survivors displaying tumors that regressed to less than half of their original size before starting to grow again.
‡Complete regression refers to the proportion of survivors displaying complete and permanent disappearance of the tumor (within 2-4 weeks after vector injection). observation. It is also possible that production of the mutant protein induced the secretion of endogenous mTNF␣ or other inflammatory proteins at levels sufficient to cause tissue necrosis but not systemic toxicity. The observation that hTNF␣ induced proliferation of the CT6 cell line was also unexpected, considering that lymphoproliferative signals are primarily induced via the p75 TNFR. However, it is possible that the longer incubation time with TNF␣ used in our assay (3 days compared with 1 day), 3 is at least partly responsible for the discrepancy between our data and the results observed by others.
The results of our studies in our murine tumor model suggest that a p75 TNFR-specific agonist may be very useful for the treatment of human cancers if the nontoxic and antitumor properties of Ad-75 can be extrapolated to human patients. The expression of such a mutant from an Ad vector would be advantageous, considering that adenoviral vectors allow for the possibility of local and transient high-level expression of the transgene over a period of several days. However, work must still be done to improve the effectiveness of this approach, possibly through the combination of TNF with other cytokines (IL-2 and IL-12) and costimulatory molecules (B7). Research on this and other approaches is presently ongoing.
